Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 679-514-8 | CAS number: 154279-60-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Short description of key information on bioaccumulation potential result:
Absorption: Absorbed throught the skin, intestinal tract and lungs.
Distribution: Widely distributed and systematically available throughtout the body.
Metabolism: There are not enought data available to estimate the route of metabolism and possible metabolites.
Excretion: Likely to be exreted feaces and urine.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
No studies relating to toxicokinetics has been conducted. The assessment of the toxicokinetic behaviour is based on the available information of the physical and chemical properties of the substance and the data obtained from animal studies.
Clearlink 1000 is readily absorbed through the skin, intestinal tract and lungs and distributed uniformly throughout the body. After absorption Clearlink 1000 is systemically available and it is expected to be extensively bioavailable.Accumulation is not expected to occur. Clearlink 1000 is likely to be excreted via feaces and urine.
Discussion on bioaccumulation potential result:
There is no valid experimental data available for the assessment of toxikokinetic behaviour of Clearlink 1000. The assessment has been made qualitatively on the basis of the physical and chemical properties and other relevant data available.
Adsorption: Clear signs of systemic toxicity (e.g. ataxia, body tremors and piloerection) have been reported after administration of test substance (trade name Clearlink 1000) in acute oral rat studies (section 7.2.1). Based on the results of these studies it can be concluded that Clearlink 1000absorbs from intestines. It is reasonable to assume, that Clearlink 1000 will also absorbs via airways, since that is the most delicate absorption route. Clear clinical signs of toxicity (e.g. lateral recumbency) were also observed in the acute dermal study in rats (section 7.2.3) and it can be concluded that Clearlink 1000 absorbs also through skin. Dose response of effects in acute oral and dermal studies can be seen as an indication of first-order kinetics in the absorption. However, the corrosive property of the substance is likely to enhance the penetration through skin and other body barriers.
Distribution:Clearlink 1000 is a lipophilic substance (log P = 1.31) with the molecular weight of 322.57 g/mol and only moderately soluble in water (section 4.8, 131 mg/L at approx. 23°C). It is likely to distribute into cells. CNS effects (ataxia, bode tremors, salivation etc.) reported in acute toxicity study by. J.O.Kuhn et al. 2001 indicate that Clearlink 1000 had distributed to CNS. Necropsy findings (discoloured lungs, liver, spleen and content of gastrointertinal tract) in the same study indicate that Clearlink 1000 has distributed to whole body. Clearlink 1000 is not likely to accumulate after frequent exposure (log P > 4). In a 28 -day repeated dose toxicity studies with the recovery period, clinical signs have resolved during the 14- or 28-day recovery period indicating that accumulation does not happen.
Metabolism: Following can be stipulated based on the structure of Clearlink 1000: Phase I reactions (oxidation, reduction and hydrolysis) are not likely to occur. Phase II metabolic reactions are conjugation reactions. The principle is to adda polar group, so the molecule becomes more water-soluble and can be excreted. These reactions are most likely to happen.
Excretion:The relative importance of the excretion depends on the physical and chemical properties of the compound and its various metabolites. Substances that are water soluble and have low molecular weight (below 300) are excreted via urine. Clearlink 1000 is moderately soluble in water and has a molecular weight over 300 therefore it is more likely to excrete via faeces.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
